

20<sup>th</sup> March 2025

BSE LIMITED Phiroze Jeejeebhoy Towers Dalal Street, Mumbai – 400001 <b>Scrip Code: BSE – AJANTPHARM 532331</b>	National Stock Exchange of India, Exchange Plaza, 5 <sup>th</sup> Floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051 <b>Scrip Code: NSE AJANTPHARM EQ</b>
--	--

**Sub: Intimation for Capacity addition under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015**

Dear Sir / Madam,

We are pleased to inform you that the Company is expanding its manufacturing capabilities by adding a state-of-the-art liquid formulation facility at its Pithampur site. This enhancement is aimed at meeting the growing global demand for the Company's liquid formulations.

The details, as required pursuant to Regulation 30 (4) (c) of the Listing Regulations, are given below:

Existing capacity	6 million Bottles per annum on single shift basis
Existing capacity utilization	175%
Proposed capacity addition	12 million bottles per annum on single shift basis
Period within which the proposed capacity is to be added	Q1 FY 2026
Investment required	Rs. 92 cr.
Mode of financing	Internal Accruals
Rationale	To meet the growing demand for global markets

We request you to take the same on your record and disseminate.

The above information is also being uploaded on the website of the Company at <https://www.ajantapharma.com/>

Thanking you,

Yours faithfully,

**GAURANG SHAH***Sr. VP – Legal & Company Secretary*